By Linda Bain, Venture Partner at Atlas Venture, as part of the From The Trenches feature of LifeSciVC “Do one thing every day that scares you” – Eleanor Roosevelt I remember the first time I consciously stepped out of my

By Julia Pian, Senior Associate at Atlas Venture, as part of the From The Trenches features of LifeSciVC As Jonathan Larson beautifully explores in “Seasons of Love” from Rent, it’s almost impossible to find the right variables to capture life

By Eric Green, CEO of Trace Neuroscience, as part of the From The Trenches feature of LifeSciVC Few neurodegenerative diseases have clearer genetic causation than Huntington’s disease (HD). And yet for decades, translating that genetic clarity into desperately needed effective

An IPO remains one of the most sought-after brass rings on the startup carousel, viewed as an important milestone on a biotech’s journey and a major financing event for powering up an emerging company.  It’s also one of the most

By Jonathan Montagu, CEO and co-founder of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC Of the recurring themes that tend to circulate in the drug development discourse,  China is a uniquely fascinating and polarizing subject.

By Arthur Tzianabos, CEO of Lifordi Immunotherapeutics, as part of the From The Trenches feature of LifeSciVC As biotech companies tackle the escalating time and cost of clinical trials, the decision to conduct early-stage, proof-of-concept studies outside the U.S. is

By Cody Tranbarger, Entrepreneur In Residence at Atlas Venture, as part of the From The Trenches feature of LifeSciVC   What if the biggest obstacle to the next generation of I&I therapeutics isn’t finding better targets — but accepting that

By Abbas Kazimi, CEO of Nimbus Therapeutics, as part of the From The Trenches feature of LifeSciVC In early 2009, when global markets were bottoming out, you can imagine what it felt like walking the halls of the JPM Healthcare

By Aimee Raleigh, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC. I’m not a resolutions person but I’ve always loved the start of the year – there is something about turning the page on

By Jason Campagna, biotech executive, as part of the From The Trenches feature of LifeSciVC I recently joined Inventiva Pharma, a late-stage company developing a therapeutic for metabolic disease and MASH, a field that is both scientifically complex and once

By, Arthur Tzianabos, CEO of Lifordi, as part of the From The Trenches feature of LifeSciVC I often hear biotech leaders refer to their company’s technology and approach in terms of the “secret sauce” or “how the sausage gets made.”

This year has truly been a rollercoaster!  The markets started off with optimism, but then collapsed into the spring, only to rebound with enthusiasm in recent months. The cadence of M&A has picked up, creating a tailwind for the sector.